These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1328 related items for PubMed ID: 15993917

  • 1. Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model.
    Meseda CA, Garcia AD, Kumar A, Mayer AE, Manischewitz J, King LR, Golding H, Merchlinsky M, Weir JP.
    Virology; 2005 Sep 01; 339(2):164-75. PubMed ID: 15993917
    [Abstract] [Full Text] [Related]

  • 2. Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge.
    Wyatt LS, Earl PL, Eller LA, Moss B.
    Proc Natl Acad Sci U S A; 2004 Mar 30; 101(13):4590-5. PubMed ID: 15070762
    [Abstract] [Full Text] [Related]

  • 3. Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox.
    Earl PL, Americo JL, Wyatt LS, Eller LA, Whitbeck JC, Cohen GH, Eisenberg RJ, Hartmann CJ, Jackson DL, Kulesh DA, Martinez MJ, Miller DM, Mucker EM, Shamblin JD, Zwiers SH, Huggins JW, Jahrling PB, Moss B.
    Nature; 2004 Mar 11; 428(6979):182-5. PubMed ID: 15014500
    [Abstract] [Full Text] [Related]

  • 4. Identification of vaccinia virus epitope-specific HLA-A*0201-restricted T cells and comparative analysis of smallpox vaccines.
    Drexler I, Staib C, Kastenmuller W, Stevanović S, Schmidt B, Lemonnier FA, Rammensee HG, Busch DH, Bernhard H, Erfle V, Sutter G.
    Proc Natl Acad Sci U S A; 2003 Jan 07; 100(1):217-22. PubMed ID: 12518065
    [Abstract] [Full Text] [Related]

  • 5. Modified vaccinia virus Ankara immunization protects against lethal challenge with recombinant vaccinia virus expressing murine interleukin-4.
    McCurdy LH, Rutigliano JA, Johnson TR, Chen M, Graham BS.
    J Virol; 2004 Nov 07; 78(22):12471-9. PubMed ID: 15507634
    [Abstract] [Full Text] [Related]

  • 6. Identification and preliminary characterization of vaccinia virus (Dryvax) antigens recognized by vaccinia immune globulin.
    Jones-Trower A, Garcia A, Meseda CA, He Y, Weiss C, Kumar A, Weir JP, Merchlinsky M.
    Virology; 2005 Dec 05; 343(1):128-40. PubMed ID: 16165184
    [Abstract] [Full Text] [Related]

  • 7. Recombinant A27 protein synergizes with modified vaccinia Ankara in conferring protection against a lethal vaccinia virus challenge.
    He Y, Meseda CA, Vassell RA, Merchlinsky M, Weir JP, Weiss CD.
    Vaccine; 2010 Jan 08; 28(3):699-706. PubMed ID: 19887133
    [Abstract] [Full Text] [Related]

  • 8. Cutting edge: mucosal application of a lyophilized viral vector vaccine confers systemic and protective immunity toward intracellular pathogens.
    Kastenmuller W, Gasteiger G, Stross L, Busch DH, Drexler I.
    J Immunol; 2009 Mar 01; 182(5):2573-7. PubMed ID: 19234150
    [Abstract] [Full Text] [Related]

  • 9. Comparative efficacy of modified vaccinia Ankara (MVA) as a potential replacement smallpox vaccine.
    Phelps AL, Gates AJ, Hillier M, Eastaugh L, Ulaeto DO.
    Vaccine; 2007 Jan 02; 25(1):34-42. PubMed ID: 16950548
    [Abstract] [Full Text] [Related]

  • 10. The nonreplicating smallpox candidate vaccines defective vaccinia Lister (dVV-L) and modified vaccinia Ankara (MVA) elicit robust long-term protection.
    Coulibaly S, Brühl P, Mayrhofer J, Schmid K, Gerencer M, Falkner FG.
    Virology; 2005 Oct 10; 341(1):91-101. PubMed ID: 16061267
    [Abstract] [Full Text] [Related]

  • 11. Postexposure immunization with modified vaccinia virus Ankara or conventional Lister vaccine provides solid protection in a murine model of human smallpox.
    Paran N, Suezer Y, Lustig S, Israely T, Schwantes A, Melamed S, Katz L, Preuss T, Hanschmann KM, Kalinke U, Erez N, Levin R, Velan B, Löwer J, Shafferman A, Sutter G.
    J Infect Dis; 2009 Jan 01; 199(1):39-48. PubMed ID: 19012492
    [Abstract] [Full Text] [Related]

  • 12. Short- and long-term immunogenicity and protection induced by non-replicating smallpox vaccine candidates in mice and comparison with the traditional 1st generation vaccine.
    Ferrier-Rembert A, Drillien R, Tournier JN, Garin D, Crance JM.
    Vaccine; 2008 Mar 25; 26(14):1794-804. PubMed ID: 18336966
    [Abstract] [Full Text] [Related]

  • 13. Development of smallpox vaccine candidates with integrated interleukin-15 that demonstrate superior immunogenicity, efficacy, and safety in mice.
    Perera LP, Waldmann TA, Mosca JD, Baldwin N, Berzofsky JA, Oh S.
    J Virol; 2007 Aug 25; 81(16):8774-83. PubMed ID: 17553867
    [Abstract] [Full Text] [Related]

  • 14. Antibodies to the A27 protein of vaccinia virus neutralize and protect against infection but represent a minor component of Dryvax vaccine--induced immunity.
    He Y, Manischewitz J, Meseda CA, Merchlinsky M, Vassell RA, Sirota L, Berkower I, Golding H, Weiss CD.
    J Infect Dis; 2007 Oct 01; 196(7):1026-32. PubMed ID: 17763325
    [Abstract] [Full Text] [Related]

  • 15. Mouse neurotoxicity test for vaccinia-based smallpox vaccines.
    Li Z, Rubin SA, Taffs RE, Merchlinsky M, Ye Z, Carbone KM.
    Vaccine; 2004 Mar 29; 22(11-12):1486-93. PubMed ID: 15063573
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine.
    Vollmar J, Arndtz N, Eckl KM, Thomsen T, Petzold B, Mateo L, Schlereth B, Handley A, King L, Hülsemann V, Tzatzaris M, Merkl K, Wulff N, Chaplin P.
    Vaccine; 2006 Mar 15; 24(12):2065-70. PubMed ID: 16337719
    [Abstract] [Full Text] [Related]

  • 18. Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naïve and vaccinia-immune individuals.
    Parrino J, McCurdy LH, Larkin BD, Gordon IJ, Rucker SE, Enama ME, Koup RA, Roederer M, Bailer RT, Moodie Z, Gu L, Yan L, Graham BS, VRC 201/203 Study Team.
    Vaccine; 2007 Feb 09; 25(8):1513-25. PubMed ID: 17126963
    [Abstract] [Full Text] [Related]

  • 19. [Development of a numerically additive combined vaccine against tetanus and smallpox].
    Mayr A, Baljer G, Wagner C, Sailer J.
    Zentralbl Bakteriol Mikrobiol Hyg A; 1985 Apr 09; 259(2):206-18. PubMed ID: 2990123
    [Abstract] [Full Text] [Related]

  • 20. Development of eczema vaccinatum in atopic mouse models and efficacy of MVA vaccination against lethal poxviral infection.
    Knitlova J, Hajkova V, Voska L, Elsterova J, Obrova B, Melkova Z.
    PLoS One; 2014 Apr 09; 9(12):e114374. PubMed ID: 25486419
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 67.